Developing, manufacturing, marketing, promoting, advertising, distributing, transferring, assigning, sharing, disclosing, selling, offering for sale, seeking hospital registration of, or submitting a response to a request for proposal for any items in the AccelFix-XT line of medical devices;
Marketing, transferring, assigning, sharing, disclosing, selling, or offering for sale any trade secrets, confidential information, testing data, specifications or measurements, applications for regulatory clearance, technologies, or manufacturing processes for, underlying, or embodied in the AccelFix-XT line of medical devices;
Seeking or obtaining any patents or other forms of intellectual property protection for any trade secrets, confidential information, testing data, applications for regulatory clearance, technologies, or manufacturing processes for, underlying, or embodied in the ProLift or AccelFix-XT lines of medical devices.
Life Spine shall forbear immediate collection, execution, or other enforcement of the Judgment so long as Aegis fully complies with the Payment Terms (subject to the Cure Period set forth in the Settlement Agreement).
Nothing in this Judgment should be read to prevent Life Spine from immediately collecting, executing, or otherwise enforcing the $17,500,000 (seventeen million, five hundred thousand dollars) identified in Paragraph III.3 upon Aegis’s failure to satisfy any of the Payment Terms (subject to the Cure Period set forth in the Settlement Agreement, if applicable).